Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (201-210 of 383) with videos related to

Pageof 39
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical SubgroupsAditya Bardia, Javier Cortés, François-Clément Bidard, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 21, 2018
Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breastMieke Van Bockstal, Kathleen Lambein, Ann Smeets, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2022
Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus FulvestrantSara M Tolaney, Masakazu Toi, Patrick Neven, et al.
Breast Cancer Research and Treatment|April 10, 2012
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifeneTrevor J Powles, Susan J Diem, Carol J Fabian, et al.
Breast Cancer Research and Treatment|July 16, 2010
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)Kathleen I Pritchard, Janusz Rolski, Zsuzsanna Papai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II studyC Kent Osborne, Patrick Neven, Luc Y Dirix, et al.
European Journal of Cancer Care|June 20, 2020
The added value of geriatric assessment in evaluating a patient's Health-Related Quality-of-Life: A study in ≥70-year-old early-stage invasive breast cancer patientsChantal Quinten, Cindy Kenis, Marije Hamaker, et al.
Clinical Breast Cancer|January 17, 2022
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 TrialGuy Jerusalem, Thomas E Delea, Migule Martin, et al.
Gynecologic Oncology|February 18, 2022
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancerAdriaan Vanderstichele, Liselore Loverix, Pieter Busschaert, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2014
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogensAnneleen Lintermans, Dirk Vanderschueren, Johan Verhaeghe, et al.
Pageof 39

Showing results (201-210 of 383) with videos related to

Sort By:
Pageof 39
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical SubgroupsAditya Bardia, Javier Cortés, François-Clément Bidard, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 21, 2018
Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breastMieke Van Bockstal, Kathleen Lambein, Ann Smeets, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2022
Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus FulvestrantSara M Tolaney, Masakazu Toi, Patrick Neven, et al.
Breast Cancer Research and Treatment|April 10, 2012
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifeneTrevor J Powles, Susan J Diem, Carol J Fabian, et al.
Breast Cancer Research and Treatment|July 16, 2010
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)Kathleen I Pritchard, Janusz Rolski, Zsuzsanna Papai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II studyC Kent Osborne, Patrick Neven, Luc Y Dirix, et al.
European Journal of Cancer Care|June 20, 2020
The added value of geriatric assessment in evaluating a patient's Health-Related Quality-of-Life: A study in ≥70-year-old early-stage invasive breast cancer patientsChantal Quinten, Cindy Kenis, Marije Hamaker, et al.
Clinical Breast Cancer|January 17, 2022
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 TrialGuy Jerusalem, Thomas E Delea, Migule Martin, et al.
Gynecologic Oncology|February 18, 2022
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancerAdriaan Vanderstichele, Liselore Loverix, Pieter Busschaert, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2014
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogensAnneleen Lintermans, Dirk Vanderschueren, Johan Verhaeghe, et al.
Pageof 39